S&P 500   3,298.88 (+0.13%)
DOW   26,777.55 (+0.42%)
QQQ   269.38 (+0.00%)
AAPL   436.87 (+0.26%)
MSFT   211.65 (-2.26%)
FB   248.91 (-1.21%)
GOOGL   1,470.31 (-0.84%)
AMZN   3,110.74 (-0.04%)
NVDA   445.06 (+1.06%)
CGC   19.12 (+0.31%)
BABA   261.73 (+1.47%)
TSLA   1,471.84 (-0.89%)
MU   51.09 (+1.39%)
GE   6.15 (+0.65%)
AMD   84.62 (+8.95%)
T   30.04 (+1.42%)
F   6.84 (+2.24%)
ACB   10.60 (+1.73%)
GILD   70.72 (-1.42%)
NFLX   507.37 (+1.75%)
DIS   117.54 (+1.02%)
BAC   24.98 (-0.04%)
BA   165.49 (+1.98%)
S&P 500   3,298.88 (+0.13%)
DOW   26,777.55 (+0.42%)
QQQ   269.38 (+0.00%)
AAPL   436.87 (+0.26%)
MSFT   211.65 (-2.26%)
FB   248.91 (-1.21%)
GOOGL   1,470.31 (-0.84%)
AMZN   3,110.74 (-0.04%)
NVDA   445.06 (+1.06%)
CGC   19.12 (+0.31%)
BABA   261.73 (+1.47%)
TSLA   1,471.84 (-0.89%)
MU   51.09 (+1.39%)
GE   6.15 (+0.65%)
AMD   84.62 (+8.95%)
T   30.04 (+1.42%)
F   6.84 (+2.24%)
ACB   10.60 (+1.73%)
GILD   70.72 (-1.42%)
NFLX   507.37 (+1.75%)
DIS   117.54 (+1.02%)
BAC   24.98 (-0.04%)
BA   165.49 (+1.98%)
S&P 500   3,298.88 (+0.13%)
DOW   26,777.55 (+0.42%)
QQQ   269.38 (+0.00%)
AAPL   436.87 (+0.26%)
MSFT   211.65 (-2.26%)
FB   248.91 (-1.21%)
GOOGL   1,470.31 (-0.84%)
AMZN   3,110.74 (-0.04%)
NVDA   445.06 (+1.06%)
CGC   19.12 (+0.31%)
BABA   261.73 (+1.47%)
TSLA   1,471.84 (-0.89%)
MU   51.09 (+1.39%)
GE   6.15 (+0.65%)
AMD   84.62 (+8.95%)
T   30.04 (+1.42%)
F   6.84 (+2.24%)
ACB   10.60 (+1.73%)
GILD   70.72 (-1.42%)
NFLX   507.37 (+1.75%)
DIS   117.54 (+1.02%)
BAC   24.98 (-0.04%)
BA   165.49 (+1.98%)
S&P 500   3,298.88 (+0.13%)
DOW   26,777.55 (+0.42%)
QQQ   269.38 (+0.00%)
AAPL   436.87 (+0.26%)
MSFT   211.65 (-2.26%)
FB   248.91 (-1.21%)
GOOGL   1,470.31 (-0.84%)
AMZN   3,110.74 (-0.04%)
NVDA   445.06 (+1.06%)
CGC   19.12 (+0.31%)
BABA   261.73 (+1.47%)
TSLA   1,471.84 (-0.89%)
MU   51.09 (+1.39%)
GE   6.15 (+0.65%)
AMD   84.62 (+8.95%)
T   30.04 (+1.42%)
F   6.84 (+2.24%)
ACB   10.60 (+1.73%)
GILD   70.72 (-1.42%)
NFLX   507.37 (+1.75%)
DIS   117.54 (+1.02%)
BAC   24.98 (-0.04%)
BA   165.49 (+1.98%)
Log in

NASDAQ:OSUROraSure Technologies Stock Price, Forecast & News

$19.19
+0.04 (+0.21 %)
(As of 08/4/2020 03:27 PM ET)
Add
Compare
Today's Range
$18.51
Now: $19.19
$19.31
50-Day Range
$9.71
MA: $13.56
$18.73
52-Week Range
$5.23
Now: $19.19
$19.44
Volume52,685 shs
Average Volume1.39 million shs
Market Capitalization$1.19 billion
P/E Ratio95.95
Dividend YieldN/A
Beta0.67
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV-1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 2000 and is based in Bethlehem, Pennsylvania.
Read More
OraSure Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.12 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:OSUR
CUSIP68554V10
Phone610-882-1820

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$154.60 million
Cash Flow$0.26 per share
Book Value$4.98 per share

Profitability

Net Income$16.66 million

Miscellaneous

Employees398
Market Cap$1.19 billion
Next Earnings Date8/5/2020 (Confirmed)
OptionableOptionable
$19.19
+0.04 (+0.21 %)
(As of 08/4/2020 03:27 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OSUR News and Ratings via Email

Sign-up to receive the latest news and ratings for OSUR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OraSure Technologies (NASDAQ:OSUR) Frequently Asked Questions

How has OraSure Technologies' stock been impacted by COVID-19 (Coronavirus)?

OraSure Technologies' stock was trading at $5.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OSUR stock has increased by 225.3% and is now trading at $19.19.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of OraSure Technologies?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for OraSure Technologies
.

When is OraSure Technologies' next earnings date?

OraSure Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for OraSure Technologies
.

How can I listen to OraSure Technologies' earnings call?

OraSure Technologies will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were OraSure Technologies' earnings last quarter?

OraSure Technologies, Inc. (NASDAQ:OSUR) issued its quarterly earnings data on Wednesday, May, 6th. The medical instruments supplier reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.06. The medical instruments supplier earned $31.60 million during the quarter, compared to the consensus estimate of $29.48 million. OraSure Technologies had a net margin of 8.06% and a return on equity of 1.69%. The business's revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.05) earnings per share.
View OraSure Technologies' earnings history
.

What price target have analysts set for OSUR?

3 equities research analysts have issued 1 year target prices for OraSure Technologies' stock. Their forecasts range from $8.00 to $19.00. On average, they expect OraSure Technologies' stock price to reach $13.67 in the next year. This suggests that the stock has a possible downside of 28.8%.
View analysts' price targets for OraSure Technologies
.

Has OraSure Technologies been receiving favorable news coverage?

News headlines about OSUR stock have been trending very negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. OraSure Technologies earned a media sentiment score of -3.6 on InfoTrie's scale. They also assigned media headlines about the medical instruments supplier a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the company's share price in the immediate future.
View the latest news about OraSure Technologies
.

Who are some of OraSure Technologies' key competitors?

What other stocks do shareholders of OraSure Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include Merit Medical Systems (MMSI), Citigroup (C), XOMA (XOMA), Energy Transfer LP Unit (ET), Overstock.com (OSTK), Ford Motor (F), CBL & Associates Properties (CBL), Alnylam Pharmaceuticals (ALNY), Celldex Therapeutics (CLDX) and Walt Disney (DIS).

Who are OraSure Technologies' key executives?

OraSure Technologies' management team includes the following people:
  • Dr. Stephen S. Tang, Pres, CEO & Director (Age 58)
  • Mr. Jack E. Jerrett, Sr. VP, Gen. Counsel & Sec. (Age 60)
  • Mr. Anthony Zezzo II, Exec. VP & Bus. Unit Leader of Infectious Disease (Age 65)
  • Mr. Brian L. Smith, Vice Chairman & EVP of Innovation - DNA Genotek, Inc. (Age 60)
  • Mr. Roberto E. Cuca, CFO & Principal Accounting Officer (Age 51)

What is OraSure Technologies' stock symbol?

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

Who are OraSure Technologies' major shareholders?

OraSure Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sicart Associates LLC (0.36%), Mackay Shields LLC (0.30%), SG Americas Securities LLC (0.21%), Envestnet Asset Management Inc. (0.18%), Brinker Capital Inc. (0.15%) and New York State Teachers Retirement System (0.13%). Company insiders that own OraSure Technologies stock include Charles W Patrick, Jack E Jerrett, Roberto Cuca and Stephen S Phd Tang.
View institutional ownership trends for OraSure Technologies
.

Which institutional investors are selling OraSure Technologies stock?

OSUR stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Sicart Associates LLC, and Quadrant Private Wealth Management LLC.
View insider buying and selling activity for OraSure Technologies
.

Which institutional investors are buying OraSure Technologies stock?

OSUR stock was purchased by a variety of institutional investors in the last quarter, including Mackay Shields LLC, SG Americas Securities LLC, Strs Ohio, New York State Teachers Retirement System, Exchange Traded Concepts LLC, Nisa Investment Advisors LLC, Brinker Capital Inc., and Comerica Bank. Company insiders that have bought OraSure Technologies stock in the last two years include Jack E Jerrett, Roberto Cuca, and Stephen S Phd Tang.
View insider buying and selling activity for OraSure Technologies
.

How do I buy shares of OraSure Technologies?

Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OraSure Technologies' stock price today?

One share of OSUR stock can currently be purchased for approximately $19.19.

How big of a company is OraSure Technologies?

OraSure Technologies has a market capitalization of $1.19 billion and generates $154.60 million in revenue each year. The medical instruments supplier earns $16.66 million in net income (profit) each year or $0.13 on an earnings per share basis. OraSure Technologies employs 398 workers across the globe.

What is OraSure Technologies' official website?

The official website for OraSure Technologies is www.orasure.com.

How can I contact OraSure Technologies?

OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at 610-882-1820 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.